The cannabis industry has been a massive disappointment in recent years, and even most industry leaders haven’t escaped the bloodbath. Take, for instance, Tilray Brands (NASDAQ:TLRY), one of the largest players in the Canadian cannabis market. Tilray has significantly underperformed the broader market over the past half-decade, losing more than 90% of its value. The company is now near record lows. Is Tilray stock a buy at current levels, or would investors be catching a falling knife?
Image source: Getty Images.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »
What happened to Tilray Brands?
Tilray Brands faces a difficult regulatory landscape in the cannabis market. Recreational use of the substance remains illegal at the federal level in the U.S. It is legal in Canada, where the company is headquartered, but that market has its own challenges.
Obtaining the proper licenses in Canada is a complex and time-consuming process. The market north of the border is also characterized by stiff competition and persistent supply gluts. Although Tilray is an industry leader, these problems have harmed its financial results. The company has diversified its business in response.
It now operates four segments: cannabis, beverage, wellness (which offers a variety of products, including hemp-based foods), and distribution (which focuses on selling pharmaceutical products in certain international markets). But even a more diversified pool of operations has done little to improve Tilray’s financial results.
In the first quarter of its fiscal year 2027, which ended on Aug. 31, Tilray’s revenue increased by 23% year over year to a record $257 million. That looks impressive at first glance, but Tilray’s top line did not grow that much organically. Earlier this year, it acquired certain assets associated with BrewDog, a craft brewery based in the United Kingdom.
This acquisition added $55.9 million in revenue to the company’s total for the period. If we subtract that from Tilray’s total revenue, its top line comes in at $201.2 million for the period, down about 4% year over year.
This includes cannabis revenue of $56.1 million, which dropped 13% year over year. Wellness revenue stayed roughly flat at $15.3 million, while distribution revenue was $84.3 million, 14% higher than the year-ago period. Beverage revenue minus the BrewDog acquisition declined 18% year over year to $45.6 million.